These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 32986841)

  • 1. An H3K4me3 reader, BAP18 as an adaptor of COMPASS-like core subunits co-activates ERα action and associates with the sensitivity of antiestrogen in breast cancer.
    Sun G; Wang C; Wang S; Sun H; Zeng K; Zou R; Lin L; Liu W; Sun N; Song H; Liu W; Zhou T; Jin F; Shan Z; Zhao Y
    Nucleic Acids Res; 2020 Nov; 48(19):10768-10784. PubMed ID: 32986841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BAP18 facilitates CTCF-mediated chromatin accessible to regulate enhancer activity in breast cancer.
    Sun G; Wei Y; Zhou B; Wang M; Luan R; Bai Y; Li H; Wang S; Zheng D; Wang C; Wang S; Zeng K; Liu S; Lin L; He M; Zhang Q; Zhao Y
    Cell Death Differ; 2023 May; 30(5):1260-1278. PubMed ID: 36828916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells.
    Hao L; Rizzo P; Osipo C; Pannuti A; Wyatt D; Cheung LW; Sonenshein G; Osborne BA; Miele L
    Oncogene; 2010 Jan; 29(2):201-13. PubMed ID: 19838210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASXL2 promotes proliferation of breast cancer cells by linking ERα to histone methylation.
    Park UH; Kang MR; Kim EJ; Kwon YS; Hur W; Yoon SK; Song BJ; Park JH; Hwang JT; Jeong JC; Um SJ
    Oncogene; 2016 Jul; 35(28):3742-52. PubMed ID: 26640146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
    Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
    Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
    [No Abstract]   [Full Text] [Related]  

  • 6. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
    Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
    Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells.
    Nathan S; Ma Y; Tomita YA; De Oliveira E; Brown ML; Rosen EM
    Breast Cancer Res Treat; 2017 Dec; 166(3):681-693. PubMed ID: 28808806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers.
    Salvati A; Giurato G; Lamberti J; Terenzi I; Crescenzo L; Melone V; Palo L; Giordano A; Sabbatino F; Roscigno G; Quintavalle C; Condorelli G; Rizzo F; Tarallo R; Nassa G; Weisz A
    Mol Cancer; 2024 Aug; 23(1):160. PubMed ID: 39113071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ubiquitin ligase RNF181 stabilizes ERα and modulates breast cancer progression.
    Zhu J; Li X; Su P; Xue M; Zang Y; Ding Y
    Oncogene; 2020 Oct; 39(44):6776-6788. PubMed ID: 32973333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
    Yu-Rice Y; Jin Y; Han B; Qu Y; Johnson J; Watanabe T; Cheng L; Deng N; Tanaka H; Gao B; Liu Z; Sun Z; Bose S; Giuliano AE; Cui X
    Oncogene; 2016 Oct; 35(41):5400-5411. PubMed ID: 27041579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYSM1 acts as a novel co-activator of ERα to confer antiestrogen resistance in breast cancer.
    Luan R; He M; Li H; Bai Y; Wang A; Sun G; Zhou B; Wang M; Wang C; Wang S; Zeng K; Feng J; Lin L; Wei Y; Kato S; Zhang Q; Zhao Y
    EMBO Mol Med; 2024 Jan; 16(1):10-39. PubMed ID: 38177530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BAP18 is involved in upregulation of CCND1/2 transcription to promote cell growth in oral squamous cell carcinoma.
    Wang X; Wang C; Yan G; Kang Y; Sun G; Wang S; Zou R; Sun H; Zeng K; Song H; Liu W; Sun N; Liu W; Zhao Y
    EBioMedicine; 2020 Mar; 53():102685. PubMed ID: 32113162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AND-34/BCAR3 differs from other NSP homologs in induction of anti-estrogen resistance, cyclin D1 promoter activation and altered breast cancer cell morphology.
    Near RI; Zhang Y; Makkinje A; Vanden Borre P; Lerner A
    J Cell Physiol; 2007 Sep; 212(3):655-65. PubMed ID: 17427198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.
    Tolhurst RS; Thomas RS; Kyle FJ; Patel H; Periyasamy M; Photiou A; Thiruchelvam PT; Lai CF; Al-Sabbagh M; Fisher RA; Barry S; Crnogorac-Jurcevic T; Martin LA; Dowsett M; Charles Coombes R; Kamalati T; Ali S; Buluwela L
    Breast Cancer Res Treat; 2011 Jul; 128(2):357-68. PubMed ID: 20730598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNF8 identified as a co-activator of estrogen receptor α promotes cell growth in breast cancer.
    Wang S; Luo H; Wang C; Sun H; Sun G; Sun N; Zeng K; Song H; Zou R; Zhou T; Cong R; Liu W; Yang L; Li D; Zhou X; Zhong X; Lin L; Jiao J; Yan G; Wang X; Min X; Cao L; Zhao Y
    Biochim Biophys Acta Mol Basis Dis; 2017 Jun; 1863(6):1615-1628. PubMed ID: 28216286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer.
    Lettlova S; Brynychova V; Blecha J; Vrana D; Vondrusova M; Soucek P; Truksa J
    Cell Physiol Biochem; 2018; 46(6):2601-2615. PubMed ID: 29763890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters.
    Giulianelli S; Vaqué JP; Soldati R; Wargon V; Vanzulli SI; Martins R; Zeitlin E; Molinolo AA; Helguero LA; Lamb CA; Gutkind JS; Lanari C
    Cancer Res; 2012 May; 72(9):2416-27. PubMed ID: 22396492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
    Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
    Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PES1 promotes breast cancer by differentially regulating ERα and ERβ.
    Cheng L; Li J; Han Y; Lin J; Niu C; Zhou Z; Yuan B; Huang K; Li J; Jiang K; Zhang H; Ding L; Xu X; Ye Q
    J Clin Invest; 2012 Aug; 122(8):2857-70. PubMed ID: 22820289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.